| Katherine White, OD | |
|
422 Clinton Ave S, Rochester, NY 14620-1103 | |
| (585) 697-5733 | |
| (585) 232-2972 |
| Full Name | Katherine White |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 422 Clinton Ave S, Rochester, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184651754 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TUV003808 (New York) | Primary |
| Provider Name | Association For The Blind And Visually Impaired-goodwill Industries Of |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053397273 PECOS PAC ID: 5698741783 Enrollment ID: O20040909000689 |
News Archive
In collaboration with colleagues at Cornell University, a team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has discovered cells with stem-cell properties in the ovary that can mutate to form tumors.
Ian M. Thompson Jr., M.D., professor and chair of urology at the U T Health Science Center, is looking for a better test - or set of tests - to diagnose prostate cancer and to distinguish between cancers that will kill men if left untreated and those that will not threaten health and do not need treatment.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.
The National HIV/AIDS Strategy represents the nation's first comprehensive plan to reduce the impact of HIV/AIDS in this country. The strategy sets specific targets and provides detailed implementation information on the steps we must take to increase access to high quality HIV/AIDS care and treatment, decrease new HIV infections, and reduce HIV-related health disparities.
The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katherine White, OD 39 Tree Brook Dr, Rochester, NY 14625-1634 Ph: (585) 586-6215 | Katherine White, OD 422 Clinton Ave S, Rochester, NY 14620-1103 Ph: (585) 697-5733 |
News Archive
In collaboration with colleagues at Cornell University, a team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has discovered cells with stem-cell properties in the ovary that can mutate to form tumors.
Ian M. Thompson Jr., M.D., professor and chair of urology at the U T Health Science Center, is looking for a better test - or set of tests - to diagnose prostate cancer and to distinguish between cancers that will kill men if left untreated and those that will not threaten health and do not need treatment.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.
The National HIV/AIDS Strategy represents the nation's first comprehensive plan to reduce the impact of HIV/AIDS in this country. The strategy sets specific targets and provides detailed implementation information on the steps we must take to increase access to high quality HIV/AIDS care and treatment, decrease new HIV infections, and reduce HIV-related health disparities.
The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.
› Verified 3 days ago
Park Sher Optical Co Of Buffalo Ny Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3180 Latta Rd, Rochester, NY 14612 Phone: 585-663-6655 | |
Abvi-goodwill Optometrist Medicare: Medicare Enrolled Practice Location: 422 Clinton Ave S, Rochester, NY 14620 Phone: 585-232-1111 Fax: 585-232-2972 | |
Dr. Pamela J. Brown, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3171 Chili Ave, Suite 100, Rochester, NY 14624 Phone: 585-889-9693 Fax: 585-889-3558 | |
Westside Eyecare Associates Optometrist Medicare: Medicare Enrolled Practice Location: 250 Mile Crossing Blvd Ste 1b, Rochester, NY 14624 Phone: 585-571-9034 Fax: 585-471-8827 | |
Dr. Harold John Roberts, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1260 Lyell Ave, Rochester, NY 14606 Phone: 585-254-0193 | |
Vincent B Graniero O D Pc Optometrist Medicare: Medicare Enrolled Practice Location: 121 Miracle Mile Dr, Rochester, NY 14623 Phone: 585-427-7960 Fax: 585-427-0451 | |
Lifetime Health Medical Group Optometrist Medicare: Not Enrolled in Medicare Practice Location: 800 Carter St, Rochester, NY 14621 Phone: 585-338-1400 Fax: 585-336-4845 |